Monopar Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, on March 31, 2025. The company reported cash, cash equivalents, and short-term investments totaling $60.2 million as of December 31, 2024, following over $55 million in net proceeds from Q4 2024 financings.
The net loss for the fourth quarter of 2024 was $10.9 million, or $2.23 per share, compared to $1.8 million, or $0.60 per share, for the fourth quarter of 2023. For the full year 2024, the net loss was $15.6 million, or $4.11 per share, compared to $8.4 million, or $3.04 per share, in 2023.
Research and development expenses for Q4 2024 increased by $8.9 million to $9.9 million, primarily due to an $8.6 million increase related to the in-licensing of ALXN1840. Monopar expects its current funds to be sufficient to continue operations at least through December 31, 2026, covering key milestones such as the ALXN1840 NDA filing and advancement of its radiopharma programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.